Table 5.
Multivariate Analyses of PFS
| Variable | Fractionation and Total Dose Included | BED Included | ||
|---|---|---|---|---|
| HR (95% CI) | P | HR (95% CI) | P | |
| Sex (female as referent) | ||||
| Male | 0.59 (0.20‐1.71) | .33 | 0.67 (0.24‐1.85) | .44 |
| Age, y | 0.96 (0.92‐1.01) | .13 | 0.97 (0.93‐1.02) | .20 |
| Time to recurrence, y | 1.14 (0.90‐1.44) | .29 | 1.16 (0.93‐1.44) | .19 |
| T classification (T1/2 as referent) | ||||
| T3/4 | 0.86 (0.26‐2.86) | .80 | 0.84 (0.25‐2.80) | .78 |
| N classification (N‐ as referent) | ||||
| N+ | 0.37 (0.09‐1.48) | .16 | 0.34 (0.09‐1.36) | .13 |
| Chemotherapy (no chemotherapy as referent) | ||||
| With chemotherapy | 1.42 (0.39‐5.24) | .60 | 1.80 (0.51‐6.29) | .36 |
| GTV dose, GyE | 0.96 (0.85‐1.09) | .55 | NA | NA |
| Fractionation (<3 GyE as referent) | ||||
| 3 GyE | 0.32 (0.08‐1.23) | .097 | NA | NA |
| BED, GyE | NA | NA | 0.94 (0.86‐1.03) | .17 |
Abbreviations: 95% CI, 95% confidence interval; BED, biological equivalent dose; GTV, gross (macroscopic) tumor volume; GyE, Gray equivalent; HR, hazard ratio; NA, not applicable; PFS, progression‐free survival.